Overcoming current limitations and expanding the reach of CAR-T therapeutics could unlock promising new treatment ...

Armed with $120 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ... which targets B-cell maturation antigen (BCMA).

To address this challenge, CTMC has established a patient material bank, enabling early-stage process development with ...

Ernexa Therapeutics’ “Trojan Horse” stem cells can infiltrate ovarian tumors in mice, boosting T cell activity and leading to ...

Non-dilutive NIH funding supports development of MiNK’s allogeneic iNKT platform for immune regulation in high-risk HSCT ...

Traditional autologous chimeric antigen receptor (CAR) T cell therapies ... to the ongoing development of high-quality cell culture reagents that are key to the clinical stage of immune cell ...

However, T cell exhaustion is a problem in the treatment of cancer, as therapeutic measures may no longer be effective. Until now, it was assumed that the body only produces such T cells in severe ...

This app note highlights a novel picodroplet-based platform that provides rapid, high-throughput assessment of cell product ...

The thymus, essential for T cell maturation, undergoes structural and functional changes over time, further diminishing immune function. Due to these issues, there is an urgent need for in-depth ...

CAR T cell therapy against CD19 and B cell maturation antigen (BCMA) is a potent immunotherapy for treating advanced B cell malignancies. It comes with a unique toxicity profile that includes cytokine ...